COMPANY
Beacon Therapeutics
Our lead asset, laru-zova, is an investigational gene therapy program for the treatment of XLRP. From company website Source · Oct 13, 2026
Raises and deals from press releases
- Raise Series C · more than $75M · announced Jan 8, 2026 Company release ↗
Source quote
- Jan 8, 2026 · Company release ↗
“Beacon Therapeutics Announces Closing of Oversubscribed Series C Financing for Over $75 Million”
- Jan 8, 2026 · Company release ↗
- Raise Series B · $170M · announced Jul 3, 2024 Company release ↗
Source quote
- Jul 3, 2024 · Company release ↗
“Beacon … Mass., July 3, 2024 – Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading ophthalmic gene therapy company with a mission to save and restore the vision of patients with blinding retinal diseases, today announced it has raised $170 million in Series B”
- Jul 3, 2024 · Company release ↗
Timeline
- Raise Private equity round — Series C: $75M (total, as published), announced Jan 8, 2026. Source: company release on GlobeNewswire. source ↗
- Raise Series C · more than $75M source ↗
- Trial start 2: A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa source ↗
- Raise Series B · $170M source ↗
- Trial start Phase 2/Phase 3: A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP source ↗
- Trial start Phase 2: A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN) source ↗
- Trial start Phase 2: A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE) source ↗
- Trial start Phase 1/Phase 2: Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations source ↗
- Trial start —: Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP) source ↗
- Trial start Phase 1/Phase 2: Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial) source ↗
- Trial start Phase 1/Phase 2: Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial) source ↗
- Trial start 1: Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis source ↗
- Trial start Phase 1/Phase 2: Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS) source ↗
- Trial start —: Clinical and Genetic Characterization of Individuals With Achromatopsia source ↗
- Trial start —: Clinical Evaluation of Patients With X-linked Retinoschisis source ↗
- Trial start Phase 2: Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency source ↗
Upcoming milestones
- Dec 31, 2029 (ESTIMATED) · 2 · A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa · NCT07174726
Funding
- Private equity round — Series C: $75M (total, as published), announced Jan 8, 2026. Source: company release on GlobeNewswire. source ↗
Clinical trials (lead sponsor) 13
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07174726 | A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa | 2 | Active, not recruiting | Sep 10, 2025 | Dec 31, 2029 (estimated) |
| NCT04850118 | A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP | Phase 2/Phase 3 | Active, not recruiting | Mar 14, 2024 | Jun 30, 2026 (estimated) |
| NCT06275620 | A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN) | Phase 2 | Enrolling by invitation | Nov 14, 2023 | 2025-11 (estimated) |
| NCT06333249 | A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE) | Phase 2 | Active, not recruiting | Apr 13, 2021 | Apr 11, 2023 (actual) |
| NCT03316560 | Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations | Phase 1/Phase 2 | Active, not recruiting | Apr 16, 2018 | Nov 9, 2023 (actual) |
| NCT02416622 | Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS) | Phase 1/Phase 2 | Completed | 2015-05 | 2019-04 (actual) |
| NCT03314207 | Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP) | Not listed | Completed | Dec 1, 2017 | Feb 10, 2022 (actual) |
| NCT02935517 | Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial) | Phase 1/Phase 2 | Unknown status (ClinicalTrials.gov) | Aug 3, 2017 | 2022-08 (estimated) |
| NCT02599922 | Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial) | Phase 1/Phase 2 | Unknown status (ClinicalTrials.gov) | Apr 11, 2016 | 2022-07 (estimated) |
| NCT01054339 | Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency | Phase 2 | Completed | 2010-06 | 2011-10 (actual) |
| NCT00749957 | Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis | 1 | Completed | Jun 17, 2009 | Sep 23, 2014 (actual) |
| NCT02331173 | Clinical Evaluation of Patients With X-linked Retinoschisis | Not listed | Completed | 2012-11 | 2016-10 (actual) |
| NCT01846052 | Clinical and Genetic Characterization of Individuals With Achromatopsia | Not listed | Completed | 2013-06 | 2017-04 (actual) |